Isis Pharmaceuticals News
Isis Pharmaceuticals' Management Presents at UBS Global Healthcare Conference (Transcript)
A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical SectorsMay 16
The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis PharmaceuticalsMay 16
ISIS Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)Seeking Alpha May 15
ISIS Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Sanofi and Regeneron Pharma announced that they started enrolling patients for two phase III trials
Isis Pharma announced that it has received a milestone payment of $3.5 million from Biogen
Shares of Celgene hit a 52-week high of $131.13 on May 13.
CARLSBAD, Calif., May 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 ...
Isis Pharmaceuticals gives biotech investors a painful reminder that dilution can come when they least expect it.